Direkt zum Inhalt
Merck

SML0005

Sigma-Aldrich

Cerivastatin sodium salt hydrate

≥98% (HPLC)

Synonym(e):

(3R,5S,6E)-7-[4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid sodium salt hydrate, Rivastatin hydrate

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

5 MG
€ 153,00
25 MG
€ 600,00

€ 153,00


Check Cart for Availability

Bulk-Bestellung anfordern

Größe auswählen

Ansicht ändern
5 MG
€ 153,00
25 MG
€ 600,00

About This Item

Empirische Formel (Hill-System):
C26H33FNNaO5 · xH2O
CAS-Nummer:
Molekulargewicht:
481.53 (anhydrous basis)
MDL-Nummer:
UNSPSC-Code:
12352200
PubChem Substanz-ID:
NACRES:
NA.77

€ 153,00


Check Cart for Availability

Bulk-Bestellung anfordern

Assay

≥98% (HPLC)

Form

powder

Optische Aktivität

[α]/D +18 to +26° in ethanol

Lagerbedingungen

desiccated

Farbe

white to tan

Löslichkeit

H2O: ≥5 mg/mL

Ersteller

Bayer

Lagertemp.

2-8°C

SMILES String

O.[Na+].COCc1c(nc(C(C)C)c(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)c1-c2ccc(F)cc2)C(C)C

InChI

1S/C26H34FNO5.Na.H2O/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4;;/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32);;1H2/q;+1;/p-1/b11-10+;;/t19-,20-;;/m1../s1

InChIKey

NJHMEKXCHXHQPP-PZLZTSNUSA-M

Allgemeine Beschreibung

Cerivastatin sodium salt hydrate belongs to the statin class of lipid lowering agents.[1] It helps in decreasing MAP kinase activation, blocking AP-1 (activator protein-1) and NF-kB (nuclear factor-kB ) binding activity, inhibiting inflammatory responses and ameliorated renal damage. It also lowers cholesterol.[2] It is metabolized by cytochrome P450 (CYP)3A4 and (CYP)2C8.[1] Cerivastatin sodium salt hydrate is linked to rhabdomyolysis.[3]

Anwendung

Cerivastatin sodium salt hydrate has been used as a supplement in cell culture.[4]
Cerivastatin sodium salt hydrate may be used in cell signaling studies.

Biochem./physiol. Wirkung

Accumulated macrophages in atherosclerotic plaques result in plaque rupture and thrombus formation. Cerivastatin suppresses the growth of macrophages and decreases the expression of matrix metalloproteinases and tissue factor molecules, thus reduces acute coronary events.[5][6]
Cerivastatin sodium is an HMG-CoA reductase inhibitor. HMG-CoA is a key enzyme in the production of cholesterol.
HMG-CoA reductase inhibitor

Leistungsmerkmale und Vorteile

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure-and cholesterol-lowering effects
Park JK, et al.
Kidney International, 58(4), 1420-1430 (2000)
Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin
Mazzu AL, et al.
Clinical Pharmacology and Therapeutics, 68(4), 391-400 (2000)
GTSE1: a novel TEAD4-E2F1 target gene involved in cell protrusions formation in triple-negative breast cancer cell models
Stelitano D, etal.
Oncotarget, 8(40), 67422-67422 (2017)
M A Crouch
American family physician, 63(2), 309-320 (2001-02-24)
Primary and secondary prevention trials have shown that use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (also known as statins) to lower an elevated low-density lipoprotein cholesterol level can substantially reduce coronary events and death from coronary heart disease. In 1987
M Aikawa et al.
Circulation, 103(2), 276-283 (2001-02-24)
Unstable atherosclerotic plaques that cause acute coronary events usually contain abundant macrophages expressing matrix metalloproteinases (MMPs) and tissue factor (TF), molecules that probably contribute to plaque rupture and subsequent thrombus formation. Lipid lowering with HMG-CoA reductase inhibitors reduces acute coronary

Artikel

Discover Bioactive Small Molecules for Lipid Signaling Research

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.